1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Mauna Kea Technologies SA Class O

Mauna Kea Technologies SA Class O

0.10
EUR
-0.01
(-10.68%)
11.17MMarket Cap
Apr 22Next Earn
Mauna Kea Technologies SA Class O
LSE:0P5I
(London Stock Exchange)

Recent

price

0.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
0.11
0.45
0.66
0.73
0.79
0.57
0.5
0.32
0.27
0.29
0.21
0.2
0.17
0.21
0.12
0.09
- -
Revenue per Share
-0.11
-0.71
-0.97
-0.84
-1
-0.84
-0.55
-0.49
-0.51
-0.61
-0.42
-0.35
-0.25
-0.08
-0.16
0.12
- -
Basic EPS, GAAP
-0.1
-0.65
-1.08
-0.78
-0.96
-0.8
-0.47
-0.5
-0.48
-0.46
-0.3
-0.3
-0.2
-0.02
-0.1
-0.04
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.51
3.85
2.96
2.18
1.3
0.87
0.56
0.69
0.32
0.01
-0.4
-0.23
-0.43
-0.28
-0.36
-0.03
-0.36
Book Value per Share
0.36
3.65
2.73
1.92
1.05
0.68
0.43
0.6
0.24
-0.07
-0.5
-0.31
-0.49
-0.31
-0.38
-0.03
-0.38
Tangible Book Value per Share
35
11
13
14
14
15
18
21
25
25
31
38
45
49
64
88
59
Basic Weighted Avg Shares
4
5
9
10
11
9
9
7
7
7
7
8
7
10
8
8
- -
Sales/Revenue/Turnover
-98.56
-161.56
-150.25
-115.48
-125.3
-151.61
-113.69
-145.18
-177.44
-175.32
-183.25
-147.68
-11.99
-54.27
-79.02
-63.18
- -
Operating Margin (%)
- -
1
1
1
1
1
1
1
1
1
1
2
1
2
2
1
- -
Depreciation Expense
-4
-8
-13
-12
-14
-13
-10
-10
-13
-15
-13
-13
-11
-4
-10
11
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-96.12
-157.68
-148.2
-115.43
-126.84
-147.92
-110.89
-153.21
-189.13
-205.52
-196
-174.61
-149.49
-35.56
-135.91
130.99
- -
Profit Margin (%)
7
51
39
29
17
13
10
20
11
10
8
11
2
-12
-24
6
-24
Working Capital
2
3
2
3
3
2
3
7
6
15
26
27
27
13
7
12
7
LT Debt
7
52
40
30
18
14
11
17
8
- -
-12
-10
-20
-17
-24
-5
-24
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-27.07
-28.46
-32.75
-57.83
-78.38
-77.19
-73.44
-103.43
-371.04
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
16
2
25
LT Borrowings
13
27
6
LT Finance Leases
- -
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
65
68
Market Capitalization
29
24
11

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
14
11
9
Cash, Cash Equivalents & STI
8
4
2
Accounts Receivable, Net
1
2
1
Inventories
3
3
4
Total Current Liabilities
27
11
33
Payables & Accruals
- -
- -
- -
ST Debt
16
2
25
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-496.74%
5.21%
-80.24%
Free Cash Flow
33.68%
70.51%
-40.5%
Net Income, GAAP
-9.26%
-20.56%
-203.55%
Sales/Revenue/Turnover
1.35%
7.14%
7.43%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
10
2024
- -
- -
8
2025
- -
- -
8

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.08
2024
- -
- -
-0.16
2025
- -
- -
0.12

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Mauna Kea Technologies S.A. (Euronext Growth: ALMKT) develops and commercializes Cellvizio, a real-time in vivo cellular imaging platform based on probe and needle-based confocal laser endomicroscopy (p/nCLE) technology; the platform includes Confocal Miniprobes inserted into standard endoscopes for cellular visualization in gastroenterology, interventional pulmonology, neurosurgery, urology, and uro-oncology; it supports applications such as accelerating cancer diagnosis, informing treatment decisions, improving surgical margins, and addressing food intolerances via the CellTolerance brand with a pay-per-use model in ambulatory surgery centers. Founded in 2000 and headquartered in Paris, France, the company operates globally with over 100,000 patient procedures performed, FDA clearances, CE marks, and Category 1 CPT codes; it targets physicians, hospitals, and drug developers in Europe, the United States, and Asia, with key partnerships including Johnson & Johnson, Telix Pharmaceuticals, and an exclusive U.S. commercialization alliance with TaeWoong Medical USA for pancreatic cyst management announced in December 2025. Recent developments encompass receipt of NMPA regulatory approval in China for the next-generation Cellvizio Gen 3 platform in November 2025; successful completion of a €6.1 million capital raise and exit from safeguard proceedings in November 2025 with strong backing from Vester Finance; launch of CellTolerance in Q4 2024 yielding a pipeline of over 40 commercial opportunities and €0.5 million in 2024 revenue targeting threefold growth in 2025; engagement of investment banks RM Global and Bucephale Finance since November 2024 to explore strategic options including M&A and licensing deals; and evaluation of options for its China joint venture with Tasly Pharmaceutical amid limited commercialization progress.